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INTRODUCTION
Only 5% of all breast cancer cases are attributed to 
the segregation of germline mutations in high penetrance 
genes within families [1-3]. The two breast cancer genes 
BRCA1 and BRCA2, account for 10-15% of the familial 
risk of breast cancer, while mutations in other high-risk 
genes PTEN, STK11, CDH1, and TP53 or in the moderate-
risk genes ATM, CHEK2, PALB2, explain around 5% of 
familial cases [4]. Thus, the great majority of families 
remain unexplained. Linkage analysis followed by 
positional cloning has been successfully applied to 
identify the high penetrance breast cancer susceptibility 
genes BRCA1 and BRCA2 [5, 6]. Subsequent linkage 
studies have been performed in non-BRCA1/2 families, 
without identifying any novel putative breast cancer 
genes [7-14]. Most other high- or moderate risk genes/
alleles have been identified through a candidate gene 
approach [15-20], while others have been identified 
through their contribution to other cancer syndromes [21, 
22]. Genome-wide association studies, mostly within the 
Breast Cancer Association Consortium (BCAC), have 
identified low-penetrance alleles that explain part of the 
remaining familial breast cancer risk [23]. In total, these 
and other studies so far have identified 94 genetic low risk 
loci, each with a typical relative risk (RR) of less than 
1.2, estimated to contribute in total 14% of the remaining 
familial risk of breast cancer [23]. Over the past a few 
years, whole-exome sequencing has been utilized to search 
for novel breast cancer susceptibility genes, assuming 
that the missing breast cancer heritability can partly be 
attributed to rare risk alleles segregating in families in an 
autosomal-dominant pattern (reviewed in [24]). Despite a 
handful of genes being reported using this technology, the 
vast majority of exome-sequenced cancer families remain 
unsolved [24]. There is evidence that there are more high- 
and low risk alleles to be identified, and that up to 28% of 
the familial risk could be attributed to still unidentified risk 
SNPs [23]. The remaining risk alleles could be rare and 
associated with smaller risks and would thus be difficult 
to find. Nevertheless, it is possible that a traditional 
strategy such as linkage analysis still might give a lead to 
new candidate susceptibility loci. We have used linkage 
and association studies in familial and sporadic breast 
cancer to define a breast cancer susceptibility locus on 
chromosome 6q.
RESULTS
Linkage analysis revealed a 2.8 Mb linked region 
in breast cancer families
In an attempt to identify new breast cancer 
susceptibility loci, a genome-wide linkage analysis was 
conducted in 96 non-BRCA1/2 families with breast or 
breast-ovarian cancer. For most families, there were few 
individuals available for study and no overall significant 
positive logarithm of odds (LOD), heterogeneity LOD 
(HLOD) or nonparametric linkage LOD (NPL LOD) 
scores were obtained for any chromosome [25]. We 
assumed that the families were heterogeneous and likely 
to segregate different risk alleles. Thus, we analyzed 
separately families with at least three affected women 
(high-risk), families with only two cases (moderate-risk) 
and families with breast cancer and other types of cancer 
(putative breast cancer syndromes). There were weakly 
positive LOD scores for the subset of 22 moderate-risk 
families, which showed HLODs above 1 for regions on 
Copyright: Jiao et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 
3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
Most non-BRCA1/2 breast cancer families have no identified genetic cause. We 
used linkage and haplotype analyses in familial and sporadic breast cancer cases to 
identify a susceptibility locus on chromosome 6q. Two independent genome-wide 
linkage analysis studies suggested a 3 Mb locus on chromosome 6q and two unrelated 
Swedish families with a LOD >2 together seemed to share a haplotype in 6q14.1. We 
hypothesized that this region harbored a rare high-risk founder allele contributing to 
breast cancer in these two families. Sequencing of DNA and RNA from the two families 
did not detect any pathogenic mutations. Finally, 29 SNPs in the region were analyzed 
in 44,214 cases and 43,532 controls from BCAC, and the original haplotypes in the 
two families were suggested as low-risk alleles for European and Swedish women 
specifically. There was also some support for one additional independent moderate-
risk allele in Swedish familial samples. The results were consistent with our previous 
findings in familial breast cancer and supported a breast cancer susceptibility locus 
at 6q14.1 around the PHIP gene.
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chromosomes 3, 6 and 14 (Figure 1a). Fine-mapping of 
those three regions confirmed and defined the regions 
to 3q25, 6q14 and 14q32. By reanalyzing a previously 
published linkage analysis in 14 large high-risk breast 
cancer families [26] but coding all cancers to define 
affected status, three additional loci showed HLOD scores 
above one, on chromosomes 3, 5 and 6 (Figure 1b). Both 
regions on chromosome 3q and 6q overlapped with those 
obtained in the previous analysis in moderate-risk families.
Fine-mapping of the 6q region was conducted using 
a total of 43 families. Only two unrelated families, 6006 
and 6043, shared a unique 2.8 Mb haplotype between 
the markers D6S1625 and rs2050660 on chromosome 
6q14.1 (Figure 2). Max LOD scores of 1.48 for family 
6006 and 0.78 for family 6043 were observed, which 
were among the highest for the families included in the 
linkage analysis. To assess whether the two families are 
related, we searched the linkage data for other shared 
and possibly linked regions and identified two more, one 
on chromosome 7 and one on chromosome 10. Fine-
mapping of both regions (data not shown) demonstrated 
that the only linked region shared was on chromosome 
6q. Thus, the families were considered not closely related. 
The finding of a shared haplotype in affected cases in 
both families together with the overall weak support 
for a region on 6q was consistent with a susceptibility 
locus within the region defined by the linkage studies, 
and in particular by the 2.8 Mb shared region flanked by 
D6S1625 and rs2050660. The locus on chromosome 6 was 
chosen for further studies.
Mutation screening of the 6q candidate region 
found no clear pathogenic mutation
A mutation screen of one affected member from 
each of 31 families (including 6006 and 6043) with 
positive LOD scores for the region revealed no clear 
pathogenic mutation in any of the six genes within this 
region. RT-PCR of mRNA from two cases from each 
of the two families 6006 and 6043 also did not detect 
any pathogenic mutation. Array comparative genomic 
hybridization (array-CGH) was performed in the two 
families, but no copy number alteration was observed 
in the candidate region. Eleven common variants were 
identified in the two families (Table 1).
Figure 1: Linkage analysis revealed genomic regions with HLOD score above one in: a) families with moderate risk of 
breast cancer and b) High risk breast cancer families with other types of cancer.
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Association studies revealed different risk 
haplotypes in Swedish breast cancer cases and 
controls
The 11 variants were used to assess whether the 
two families’ haplotype was associated with breast 
cancer risk. We first performed a pilot study using the 31 
linked familial cases included in the mutation screen and 
95 healthy controls and found one rare risk-associated 
haplotype (estimated frequency 7.7% in cases and 0.3% 
in controls, odds ratio (OR) = 26.5, p = 0.0005). Although 
the haplotype was not the same as in the two original 
families, the existence of a risk haplotype among the 
Swedish families suggested a Swedish founder mutation 
at this locus.
In the next larger association study, 9 of 11 SNPs 
were successfully genotyped in 800 breast cancer cases 
and 1,750 healthy controls. There was no risk haplotype 
found by comparing all cases to all controls. However, 
one rare (3%) risk haplotype was suggested (p = 0.03) 
when the analysis included only the 496 familial breast 
cancer cases versus all 1,750 controls. This result weakly 
supported the hypothesis of a risk factor in the region, 
although the haplotype was still not the same as that seen 
in the two original families.
Association studies verified the risk haplotypes 
and identified new candidates in European breast 
cancer cases and controls
To search for additional support for the region and 
for the two families’ haplotype, we selected SNPs from an 
extended region around these 11 markers to be included 
in a custom genotyping array project (iCOGS) of BCAC 
(http://bcac.ccge.medschl.cam.ac.uk/). In total 29 SNPs in 
the region from rs9343798 to rs7768535 were successfully 
genotyped in 100,165 BCAC samples (including 50,009 
cases and 50,156 controls) as well as in the two original 
families (6006 and 6043) to search for a confirmation of 
the hypothesized risk haplotype identified in these two 
families.
The familial 29-SNP risk haplotype in the respective 
families was identical except for two markers (Table 2). 
After excluding studies of Asian women, BCAC data from 
44,214 cases vs. 43,532 controls was first analyzed as a 
whole for a haplotype using the 29 markers, and next the 
following sub-analyses were studied, postmenopausal (age 
> 60, 16,878 cases), early onset (age < 50, 12,305 cases), 
estrogen receptor (ER) positive (26,546 cases) and ER 
negative (7,194 cases). Two risk haplotypes were found 
for all BCAC, one (I) same as in family 6006 (Table 2). 
The 6006 haplotype (I) was also associated with risk of 
breast cancer before age 50. The second haplotype (II) 
was associated with risk of ER-positive disease. A third 
haplotype (III) was associated with risk of ER-positive 
and late-onset (after age 60) breast cancer, and a fourth 
haplotype (IV) was suggested in ER-positive disease 
only (Table 2). Thus, the sub-analysis of ER-positive 
breast cancer using BCAC data identified three different 
haplotypes (Table 2).
The Swedish BCAC studies are the most likely to 
have included patients with a Swedish founder mutation 
with risk haplotypes around it. In the SASBAC study 
(1,163 cases vs. 1,378 controls) recruiting postmenopausal 
cases, the same haplotype as in family 6043 was associated 
with breast cancer risk (Table 2). In the KARBAC study 
(722 cases vs. 662 controls) with a predominance of 
familial breast cancer cases, it was suggested a different 
susceptibility haplotype, and also a higher associated risk 
compared to the other risk haplotypes (Table 2). Finally, 
the third Swedish study pKARMA (4,553 cases vs. 5,537 
controls), with consecutive cases from a mammography 
cohort, suggested yet another risk-associated haplotype 
(Table 2). The result altogether further supported the 
Table 1: Sequence variants shared by families 6006 and 6043 from Sanger sequencing.
Genomic variantsa dbSNP ID Gene Variant type MAFb
chr 6: 79595097 A>G rs6908105 IRAK1BP1 Synonymous 0.27
chr 6: 79656562 A>T rs2275291 PHIP Synonymous 0.24
chr 6: 79656570 C>T rs2275290 PHIP Synonymous 0.28
chr 6: 79657391 C>T rs1984195 PHIP Synonymous 0.51
chr 6: 79664440 A>G rs9443632 PHIP Intronic 0.52
chr 6: 79664748 A>G rs10455356 PHIP Intronic 0.52
chr 6: 79675701 T>C rs9350797 PHIP Missense p.L1093P 0.22
chr 6: 79679577 T>C rs7742431 PHIP Synonymous 0.55
chr 6: 79695029 G>A rs1890229 PHIP Intronic 0.52
chr 6: 79707923 G>A rs11752126 PHIP Intronic 0.39
chr 6: 79752792 T>C rs9343863 PHIP Intronic 0.51
a Genomic coordinates were based on GRCh37.
b Minor allele frequency (MAF) obtained from the 1000 Genomes Project.
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hypothesis of a breast cancer risk locus on chromosome 
6q14.
The risk-associated haplotype identified using 
KARBAC was not studied further since the 29 SNPs were 
only genotyped in non-related individuals and relatives 
from the two original families. We hypothesized that 
the distribution of risk haplotypes of different sizes over 
a locus could reflect one or several risk alleles. Thus, 
we performed a haplotype analysis in KARBAC on 
sliding windows over the 29 SNPs. The result suggested 
the existence of one risk allele in the PHIP gene 
(Supplementary Figure 1a). Sliding-window haplotype 
analyses were also performed for the whole BCAC and 
the other Swedish studies SASBAC and pKARMA (Table 
2 and Supplementary Figure 1). The BCAC risk haplotype 
I (in BCAC and in BCAC < 50), same as the one in family 
6006, showed a similar result as in KARBAC, one risk 
allele in the PHIP gene (Supplementary Figure 1b). The 
almost same risk haplotype, originally identified in family 
6043 and observed using SASBAC data, instead suggested 
involvement of one locus in the 5’-part of the PHIP gene 
as well as another locus proximal to PHIP (Supplementary 
Figure 1c). The same analysis for the other haplotypes 
BCAC (II, III and IV) and pKARMA suggested three 
Table 2: Candidate risk haplotypes identified in BCAC and three Swedish studies in comparison to the familial 
haplotypes. 
Candidate risk haplotypes
Frequency 5.1% 5.0% 8.3% 9.0% 1.7% 1.7% 1.3% 21.3% 1.7% 5.6%
OR 1.06 1.09 1.04 1.04 1.11 1.12 1.13 1.19 1.93 1.24
p-value 0.03 0.02 0.04 0.04 0.05 0.02 0.02 0.01 0.02 0.006
SNP 6006 6043 BCACI
BCAC
<50 y
I
BCAC
II
BCAC
ER+
II
BCAC
>60 y
III
BCAC
ER+
III
BCAC
ER+
IV
SASBAC KARBAC pKARMA>60 y
rs9343798 G G G G A A A A A G A G
rs7760429 G G G G G G G G A G A G
rs9350774 G G G G A A A A A G A G
rs9448560 G G G G G G G G G G G A
rs1507152 G G G G G G G G G G A A
rs9361440 A A A A C C A A A A A A
rs9343824 G G G G A A A A G G A A
rs6454084 G G G G G G G G G G G A
rs955765 G G G G G G G G G G A G
rs9352664 A A A A C C C C A A C C
rs9361459 A A A A A A G G A A G G
rs9448595 G G G G G G G G G G G G
rs2275290 G G G G G G A A G G A G
rs10943606 C C C C C C C C C C A C
rs9350797 A A A A A A G G A A G A
rs10943611 A A A A G G A A A A A A
rs1415862 A A A A A A A A A A A G
rs1415863 G G G G G G G G G G G A
rs12208915 G G G G G G G G G G A G
rs9448607 A A A A G G G G A A G G
rs11754374 C C C C C C A A C C A C
rs10455120 A C A A A A A A A C A A
rs12197385 C A C C C C C C C A C C
rs1415310 A A A A G G G G A A G G
rs9443645 A A A A G G G G A A G G
rs12208017 A A A A A A C C A A C A
rs9361491 G G G G A A A A G G A G
rs6454096 G G G G G G A A G G A G
rs7768535 G G G G G G A A G G A G
The two families are different on markers rs10455120 and rs12197385. Sub-analyses on postmenopausal (>60 y), early onset 
(<50 y), ER positive (ER+) and negative (ER-) cases were performed in all four studies. Estimated haplotype frequency in 
the control group, OR and association p-value was shown for each risk haplotype. Four risk haplotypes revealed in the BCAC 
study were referred as I, II, III and IV.
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possible loci (BCAC III and pKARMA), one proximal 
to, one in, and one distal to PHIP. The BCAC II and IV 
haplotypes both focus on the suggested risk allele distal to 
PHIP (data not shown).
We had previously tested for mutations in the exonic 
regions over the whole haplotype in the two families 
without finding any candidate mutation. A targeted 
genome sequencing approach was subsequently applied 
to a 2.8 Mb region in the two original families (from 
rs9447790 to rs2655685) and the lack of clear pathogenic 
mutations was confirmed. The two families shared many 
markers in the region of the haplotype. It was not possible 
to define the pathogenic mutation in either of the two 
haplotype regions (Supplementary Table 1).
Figure 2: Pedigrees of the families 6006 and 6043 showing the haplotypes of selected family members (the families’ risk 
haplotype is indicated in grey shade).
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DISCUSSION
The study was based on the early finding that two 
unrelated families shared one haplotype for a risk locus 
on chromosome 6q. It was also hypothesized, based on the 
family history and the design used (linkage analysis), that 
they shared a mutation in a rare, high-risk breast cancer 
gene. In the end, it was clear that they did not share an 
identical haplotype. Family 6006 had one identical to a 
risk haplotype in BCAC, in particular for those with early 
onset and family 6043 was similar to one quite prevalent 
(frequency 21%) haplotype in Swedish postmenopausal 
cases (SASBAC) (Table 2). It was also suggested that the 
families had different mutations, 6006 within the PHIP 
gene and 6043 one or two proximal and distal to the PHIP 
gene (Supplementary Figure 1).
This risk locus on 6q was first the result from two 
different linkage studies in familial breast cancer and 
chosen for further study, not because of a statistically 
significant LOD score, but rather that the locus was 
suggested from two separate studies, and that two 
unrelated families seemed to share a unique haplotype 
at this locus. The lack of statistically significant loci in 
linkage analysis in breast cancer is often seen and perhaps 
results from a complex inheritance pattern in genetically 
unsolved familial breast cancer. Sanger sequencing 
excluded an exome-based mutation at the locus in the 
two families. However, early small association studies 
gave support for a familial risk haplotype in the region. 
This first association study performed using only 31 
samples, selected because of possible linkage to the locus, 
suggested a clear association to this locus (p = 0.0005). 
However, the evidence was much weaker when sample 
sizes increased (p = 0.03). All the time the focus was on 
familial samples, which might explain the difficulties to 
identify the two original families’ haplotypes since they 
are not over-represented among familial samples (Table 
2). It was not until it was possible to study also sporadic 
breast cancer samples within BCAC that evidence was 
found for the families’ haplotypes to act as risk alleles 
in breast cancer. It was most clear in SASBAC with 
postmenopausal cases.
The target for the risk association is between our 
original borders D6S1625 - rs2050660 and in this region 
there are several genes such as HTR1B, MEI4, IRAK1BP1, 
PHIP, HMGN3, LCA5 and SH3BGRL2 as well as several 
different RNAs. The HTR1B gene has been suggested 
to be involved in breast cancer progression [27] and the 
HMGN3 gene has been published to be upregulated in 
breast cancer cell lines [28]. None is currently known to 
be associated with breast cancer risk. We were mostly 
interested in the region of the PHIP gene and have focused 
our investigation around it because of the shared haplotype 
in the two families hypothesized as a risk haplotype over 
this region. In fact, the PHIP gene was suggested to be 
target of the risk allele in KARBAC with familial cases 
and BCAC early onset cases (Supplementary Figure 1a 
and 1b). It has been reported that pleckstrin homology 
domain interacting protein (PHIP) promotes tumor 
metastasis through Akt activation in murine melanoma 
[29]. Forward genetic screen in mice with malignant 
peripheral nerve sheath tumor also identified the PHIP 
gene as a common integration site, indicating its role as 
a candidate driver gene in tumorigenesis [30]. The PHIP 
gene has been associated with melanoma progression, 
and overexpression has been suggested to serve as an 
independent adverse predictor of survival in melanoma 
[29]. To our knowledge there is not yet any study on PHIP 
gene in relation to breast cancer prognosis or risk. We did 
find one unique missense mutation c.A3733G (p.I1245V) 
in one family (6082). This mutation did not segregate in 
affected members in this family. The other two missense 
variants in this gene, rs11547228 (p.T874I) and rs7747479 
(p.G663V), did not show any increased frequency in 
the 48 breast cancers subjected to targeted sequencing 
compared to that in a general population (1000 Genomes 
Project). Although none of the 29 SNPs shows statistically 
significant evidence of being an eQTL in breast mammary 
tissue in GTEx [31], ENCODE project has revealed that 
this locus contains multiple regulatory elements including 
promoters, enhancers, transcription factor binding sites, 
open chromatin regions, DNaseI hypersensitivity sites, 
etc [32]. It is possible that an involvement of the gene is 
related to its expression level.
Linkage analysis typically has been used to find 
high-penetrance disease [4, 5] while association studies 
typically reveal low-penetrance risk loci [23]. Our studies 
were first set up to detect a highly penetrant breast cancer 
susceptibility gene using familial breast cancer. This 
approach was not successful (negative Sanger sequencing 
in all genes in the region) and it was clear that association 
studies might be more powerful than linkage studies 
(statistically significant support for a risk haplotype in 
our early studies). Thus, the candidate region was tested 
using association analysis within the iCOGS project in 
BCAC. The finding of several low risk haplotypes in 
this risk locus demonstrated also different risks, with an 
estimated OR of 1.1 for the common and typical low-risk 
haplotypes in SASBAC and BCAC, while the moderate-
risk haplotype in the familial cohort KARBAC had an 
OR of almost 2 and was rare. Low-risk loci often do not 
involve exonic mutations but are frequently distributed 
over gene-free regions [23], which makes it more difficult 
to clearly define the disease-causing mutation. Thus, no 
clear pathogenic mutation was identified on the haplotype 
with too many candidate mutations over the region.
The project has been carried out over a long period 
and the methods used were appropriate at the time 
(Supplementary Figure 2). The first linkage analysis was 
set up in 1998, completed in 2002 and chose the best 
technique and markers available at the time [25]. The 
second linkage study was completed much later and used 
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more informative markers [26]. Still, in spite of the overall 
lack of positive LOD scores, both studies suggested two 
loci (on chromosomes 3 and 6) with weak evidence, but 
one was of particular interest because of the two families 
with the shared haplotype and early findings of same gene 
expression profiles in tumors (unpublished data).
Linkage analysis has shown its limitations to define 
novel loci for a heterogeneous and complex disease, such 
as breast cancer [7-14, 25, 26]. Association studies will 
typically provide evidence for low-risk alleles and the 
clinical impact of these alleles are yet to be determined 
[23]. Today next-generation sequencing presents new 
opportunities to use direct sequencing of patients with 
familial breast cancer [33-36]. We have used several 
strategies to study a small region on chromosome 6q14 
and found support for a breast cancer susceptibility locus, 
related to the PHIP gene, with low and moderate risk 
profiles. Further studies of patients with the identified 
haplotypes and their tumors will be necessary before 
it is possible to estimate the importance of this locus. 
Haplotype analysis in populations with a homogenous 
genetic background will be valuable to further define this 
locus.
MATERIALS AND METHODS
Families for linkage studies and cases for 
association studies
Non-BRCA1/2 breast cancer families were recruited 
through the Cancer Counseling Clinic at the Karolinska 
University Hospital, Solna, Sweden. The first linkage 
study involved 272 members from 96 non-BRCA1/2 
breast cancer families, including 232 breast cancer patients 
(age of diagnosis 30-72 years, mean 54.7 years). These 
families were selected if two or more first- or second-
degree relatives were affected with only female breast 
cancer, and if the proband had counseled a two to four 
times increased risk for the disease compared to the 
normal population, no age limitation required. Twenty of 
these families have two affected cases, 42 families have 
three cases, 24 families have four cases, eight families 
have five cases and two families have six cases, with an 
average of 3.2 cases per family. Nine of the families were 
breast-ovarian cancer families. No other types of cancer 
were presented in this set of families.
The second linkage study was based on the cohort of 
14 large hereditary non-BRCA1/2 breast cancer families 
with also other cancers in the family [26]. DNA was 
available from 96 family members, including 50 affected 
by breast cancer. Linkage analysis tested patients were 
grouped as breast cancer families where only breast 
cancer cases were coded as affected, and also using cancer 
syndrome criteria wherein patients having breast, cervical, 
endometrial, colorectal, prostate or any other cancers were 
coded as affected.
The association studies used 300 familial cases 
identified and recruited as described above and 500 
consecutive breast cancer cases from a breast cancer clinic 
at Södersjukhuset in Stockholm [37]. The consecutive 
cases were recruited at diagnosis and can be categorized 
as familial or sporadic cases if a family history of cancer 
was available. Blood samples were obtained from affected 
family members with informed consent. Blood donors 
from the same hospital and cancer-free spouses served as 
controls. Genomic DNAs were extracted using standard 
phenol extraction procedures.
The study was undertaken in accordance with the 
Swedish legislation of ethical permission (2003:460) and 
according to the decision in the Stockholm regional ethical 
committee in Stockholm (Dnr: 1992/207. 1997/205, 
1998/232, 2000/291).
Linkage analysis in 96 breast and breast-ovarian 
cancer families
Genotyping was carried out using Linkage Mapping 
Set v2.0- MD10 (Applied Biosystems). 400 fluorescent-
labeled microsatellite markers covered the whole genome 
with an average resolution of 10 cM. The average 
heterozygosity of these markers was 0.76 in our sample 
set. The amplified fragments were separated on an ABI 
377 automated sequencer (Applied Biosystems) together 
with internal size standard. Electrophoretic data were 
analyzed using GeneScan (v3.1) and Genotyper (v2.0) 
softwares (Applied Biosystems).
Genotyping data were first checked for consistency 
by using PedCheck [38]. Homozygosity tests were 
performed to further check marker quality and genotyping 
errors. Model-dependent multipoint LOD scores were 
generated using GeneHunter v2.1 [39] complemented by 
LINKMAP of FASTLINK [40-42]. Two-point LOD scores 
were performed using the MLINK of the FASTLINK 
package because multipoint LOD scores are always 
affected by flanking markers and marker density. We 
assigned an autosomal dominant inheritance model in the 
linkage analysis, with only female breast cancer as the 
affected phenotype. The gene frequency was set to 0.003. 
Age-dependent penetrance for carriers was applied. The 
penetrance was set to 0.01 for unaffected males, 0.20 for 
unaffected females below 40 years old, 0.40 for unaffected 
females between 40-65 years old and 0.60 for unaffected 
females above 65 years old. Marker allele frequencies 
were estimated by PedCheck from individuals in each 
pedigree. Published map distances from Marshfield [43] 
were used in the analysis. The overall LOD scores were 
maximized to allow for heterogeneity (HLOD). At each 
locus a maximum HLOD and a corresponding estimate of 
the proportion of families linked were obtained.
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Linkage analysis in 14 large breast cancer families 
with other cancers
The second linkage analysis was carried out in 14 
large breast cancer families with other cancer types using 
a previously published approach [26] with modifications. 
We defined affected status as: 1) breast cancer only; 2) 
breast cancer and other cancers in two separate analyses, 
in order to search for additional evidence of risk loci 
associated with breast cancer.
Fine-mapping of the chromosome 6q14 locus 
following linkage analyses
Markers were selected throughout the chromosome 
6q14 region revealed by the linkage analyses for fine-
mapping in additional breast cancer families. Primers 
for the markers were obtained from dbSTS (http://www.
ncbi.nlm.nih.gov/projects/dbSTS/) and were labeled with 
6-Fam Fluorescein modification at the 5’ end of forward 
primers. The amplified markers were analyzed on an ABI 
Prism 377, 3130xL or 3500xL Genetic Analyzer (Applied 
Biosystems). Softwares GeneScan (v3.1R), GeneMapper 
(v3.7 or 4.1) and GenoTyper (v2.0) was used to analyze 
the peaks.
Sanger sequencing of linked familial breast cancer 
samples
Genomic DNA from one affected member from 
each of the 31 families with positive LOD scores for 
the linked region, including families 6006 and 6043, 
was PCR-amplified and sequenced for the six genes 
within this region (HTR1B, IRAK1BP1, PHIP, HMGN3, 
C6ORF152 and SH3BGRL2) for all exons including exon/
intron boundaries, 5’ and 3’ UTR sequences and putative 
promoter regions. All genes were successfully amplified 
and sequenced. RT-PCR analysis was carried out using 
mRNA from EBV-transformed lymphocytes from two 
cases in each of the families 6006 and 6043 to detect 
aberrant splicing patterns or large insertions / deletions.
Copy number analysis by array-CGH
A custom array-CGH was designed for exon specific 
analysis of deletions and duplications in the chromosome 
6 region (77462539-80350534). Agilent Technologies 
Suredesign was used to design a targeted 4x180K 
array (Oxford Gene Technologies, Oxfordshire, UK). 
Experiments were performed at the Department of Clinical 
Genetics at Karolinska University Hospital, Stockholm, 
Sweden according to the manufacturer’s protocol. 
Slides were scanned using the Agilent Microarray 
Scanner (G2505C, Agilent technologies, USA). Raw 
data were normalized using Feature Extraction Software 
(10.7.3.1, Agilent Technologies, USA), and log2 ratios 
were calculated by dividing the normalized intensity in 
the sample by the mean intensity across the reference 
sample. The log2 ratios were plotted and segmented by 
circular binary segmentation in the CytoSure Interpret 
software (Oxford Gene Technology, Oxfordshire, UK). 
Oligonucleotide probe positions were annotated to Human 
Genome Assembly hg19.
Association study using 9 SNPs from Sanger 
sequencing
Nine variants (shared sequence variants in family 
6006 and 6043) used for the association study in 800 cases 
and 1750 controls were rs2275291, rs2275290, rs1984195, 
rs9443632, rs10455356, rs9350797, rs7742431, rs1890229 
and rs11752126 genotyped by DeCODE, Iceland.
Genotyping of BCAC samples
Genotyping within BCAC and iCOGS used a 
custom Illumina array with 211,155 SNPs. Genotyping, 
allele calling, quality control and principal components 
analysis for the iCOGS study are described in detail in 
Michailidou et al. [23]. In total 29 SNPs were successfully 
genotyped for the 6q region. Haplotype association 
analysis was performed on the whole BCAC study as 
well as on three Swedish subpopulations independently. 
Haplotype frequency was estimated for all but Asian 
samples and for all 29 markers. P-values were calculated 
by Plink v.1.07 [44].
Capture sequencing
Capture sequencing of 48 familial breast cancer 
patients was performed by Axeq Technologies, USA 
using a SureSelect target enrichment process followed by 
100 bp paired-end sequencing on an Illumina HiSeq2000 
sequencer. After sequencing, bioinformatics analysis of 
the FASTQ files included alignment of sequence reads to 
the reference human genome (GRCh37/hg19) using BWA 
and SAMTools, applying GATK [45-47] base quality 
score recalibration, indel realignment, duplicate removal, 
variant calling and annotation (dbSNP and 1000 Genome 
Project).
Abbreviations
SNP: single nucleotide polymorphism; NPL: non-
parametric linkage; LOD: logarithm of odds; HLOD: 
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Morgan.
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